

Claims of the Asserted '482 Patent	Corresponding Claim(s) of the '576 Application (as of December 8, 2022 Amendment)
1. A method of treating acne vulgaris, the method comprising topically applying a pharmaceutical composition once per day to an affected area of a body of a subject suffering from acne vulgaris, wherein: the composition comprises tazarotene at a concentration of about 0.045 percent by weight of the composition as a sole active pharmaceutical ingredient the composition is an oil-in-water emulsion lotion comprising an oil phase and an aqueous phase; the oil phase comprises a dicarboxylic acid ester and a mineral oil at a total concentration of 10-12 percent by weight of the composition; the aqueous phase comprises water and a carbomer homopolymer, wherein the concentration of the carbomer homopolymer is 0.5-0.7 percent by weight of the composition; and the composition further comprises a polymeric emulsifier at a concentration of 0.3-0.5 percent by weight of the composition.	1. (Previously presented) A topical pharmaceutical composition for treating acne, comprising: a sole active pharmaceutical ingredient consisting of tazarotene at a concentration of 0.045 percent by weight of the composition; wherein said composition is an oil-in-water emulsion lotion comprising an oil phase and an aqueous phase, wherein the oil phase comprises a dicarboxylic acid ester and a mineral oil, wherein the aqueous phase comprises water and a carbomer homopolymer, wherein the composition further comprises a polymeric emulsifier, and wherein the tazarotene is in solution in the oil phase. 6. (Previously presented) The topical pharmaceutical composition of claim 1, wherein: the dicarboxylic acid ester and the mineral oil are present in a total amount of 10-12 percent by weight of the composition,

Claims of the Asserted '482 Patent	Corresponding Claim(s) of the '576 Application (as of December 8, 2022 Amendment)
	the carbomer homopolymer is present in an amount of 0.5-0.7 percent by weight of the composition, and the polymeric emulsifier is present in an amount of 0.3-0.5 percent by weight of the composition.
2. The method of claim 1, wherein the dicarboxylic acid ester in the oil phase is diethyl sebacate.	7. (Previously presented) The topical pharmaceutical composition of claim 1, wherein the dicarboxylic acid ester in the oil phase of the emulsion is diethyl sebacate.
3. The method of claim 1, wherein the oil phase comprises diethyl sebacate and light mineral oil.	10. (Previously presented) The topical pharmaceutical composition of claim 1, wherein the oil phase comprises diethyl sebacate and light mineral oil.
4. The method of claim 1, wherein said applying is carried out for at least eight weeks.	
5. The method of claim 1, wherein said applying is carried out for at least twelve weeks.	
6. The method of claim 1, wherein said applying is carried out for twelve weeks.	
7. The method of claim 1, wherein the tazarotene is in solution in the oil phase of the oil-in-water emulsion lotion.	See claim 1 of the '576 application <i>supra</i>
8. The method of claim 1, wherein the composition has a pH of about 4 to about 6.	12. (Original) The topical pharmaceutical composition of claim 1, having a pH of about 4 to about 6.
9. The method of claim 1, wherein the composition consists essentially of: 0.045 weight % tazarotene; diethyl sebacate; light mineral oil; sorbitan monooleate; sorbitol solution, 70%;	27. (Previously presented) The topical composition of claim 1 consisting essentially of: 0.045 weight% tazarotene; 2.5 -3.5 weight% diethyl sebacate; 7.5-8.5 weight% light mineral oil; 0.05-0.2 weight% sorbitan monooleate; 10-11 weight% sorbitol solution, 70%;

Claims of the Asserted '482 Patent	Corresponding Claim(s) of the '576 Application (as of December 8, 2022 Amendment)
methylparaben; propylparaben; edetate disodium dihydrate; carbomer copolymer type B; carbomer homopolymer type A; sodium hydroxide; purified water.	0.1-0.2 weight% methylparaben; 0.02-0.04 weight% propylparaben; 0.03-0.06 weight% edetate disodium dihydrate; 0.3-0.05 weight% carbomer polymer type B; 0.5-0.7 weight% carbomer homopolymer type A; sodium hydroxide, q.s. to pH 5.5 ±0.5; and purified water, q.s. to 100 weight%.
10. The method of claim 1, wherein the composition consists essentially of: 0.045 weight % tazarotene; 2.5-3.5 weight % diethyl sebacate; 7.5-8.5 weight % light mineral oil; 0.05-0.2 weight % sorbitan monooleate; 10-11 weight % sorbitol solution, 70%; 0.1-0.2 weight % methylparaben; 0.02-0.04 weight % propylparaben; 0.03-0.06 weight % edetate disodium dihydrate;	27. (Previously presented) The topical composition of claim 1 consisting essentially of: 0.045 weight% tazarotene; 2.5 -3.5 weight% diethyl sebacate; 7.5-8.5 weight% light mineral oil; 0.05-0.2 weight% sorbitan monooleate; 10-11 weight% sorbitol solution, 70%; 0.1-0.2 weight% methylparaben; 0.02-0.04 weight% propylparaben; 0.03-0.06 weight% edetate disodium dihydrate;

Claims of the Asserted '482 Patent	Corresponding Claim(s) of the '576 Application (as of December 8, 2022 Amendment)
0.3-0.5 weight % carbomer copolymer type B; 0.5-0.7 weight % carbomer homopolymer type A; sodium hydroxide, q.s. to pH 5.5±0.5; and purified water, q.s. to 100 weight %.	0.3-0.05 weight% carbomer polymer type B; 0.5-0.7 weight% carbomer homopolymer type A; sodium hydroxide, q.s. to pH 5.5 ±0.5; and purified water, q.s. to 100 weight%.
11. A method of treating acne vulgaris, the method comprising topically applying a pharmaceutical composition to an affected area of a body of a subject suffering from acne vulgaris; wherein the composition consists essentially of: 0.045 weight % tazarotene; 2.97 weight % diethyl sebacate; 8.03 weight % light mineral oil; 0.1 weight % sorbitan monooleate; 10.7 weight % sorbitol solution, 70%; 0.17 weight % methylparaben; 0.03 weight % propylparaben; 0.05 weight % edetate disodium dihydrate; 0.4 weight % carbomer copolymer type B;	27. (Previously presented) The topical composition of claim 1 consisting essentially of: 0.045 weight% tazarotene; 2.5 -3.5 weight% diethyl sebacate; 7.5-8.5 weight% light mineral oil; 0.05-0.2 weight% sorbitan monooleate; 10-11 weight% sorbitol solution, 70%; 0.1-0.2 weight% methylparaben; .02-0.04 weight% propylparaben; 0.03-0.06 weight% edetate disodium dihydrate; 0.3-0.05 weight% carbomer polymer type B;

Claims of the Asserted '482 Patent	Corresponding Claim(s) of the '576 Application (as of December 8, 2022 Amendment)
0.6 weight % carbomer homopolymer type A; sodium hydroxide, q.s. to pH 5.5±0.5; and purified water, q.s. to 100 weight %.	0.5-0.7 weight% carbomer homopolymer type A; sodium hydroxide, q.s. to pH 5.5 ±0.5; and purified water, q.s. to 100 weight%.